Welcome to the CJU website » LOG IN


How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer
Division of Urology, McMaster Institute of Urology, Hamilton, Ontario, Canada
Aug  2016 (Vol.  23, Issue  4, Pages( 8388 - 8394)
PMID: 27544566


Text-Size + 

  • Abiraterone acetate (AA) is a selective irreversible inhibitor of CYP 17, a key enzyme in androgen biosynthesis. The efficacy and safety of AA in improving survival and quality of life in metastatic castration resistant prostate cancer (mCRPC) has been demonstrated in two landmark clinical trials (COU-AA-301 and COU-AA-302). This article will review the rationale, pharmacology, clinical indications and contraindications, administration, and adverse effects of AA administration in mCRPC.